ENGN
enGene Holdings
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ENGN Profile
Engene Holdings Inc.
A clinical-stage biotechnology company focused on non-viral gene therapies
4868 Rue Levy, Suite 220 Saint-Laurent, QC, Canada, H4R 2P1
--
EnGene Holdings Inc., was registered under the federal laws of Canada as 14963148 Canada Inc., on April 24, 2023, and changed its name to enGene Holdings Inc., on May 9, 2023. The company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The company is developing non-viral gene therapies based on its new and proprietary dual-derived chitosan, or "DDX" gene delivery platform, which allows local delivery of multiple gene cargoes directly to mucosal tissues and other organs.